Home
NewsNewsThe 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
The 2027 Title X Notice of Funding Opportunity (NOFO) PA-FPH-27-001 signals a significant shift in federal family planning priorities, placing a 10452 renewed emphasis on addressing infertility and supporting family formation. Recognising what it terms a "growing infertility crisis," the Office of Population Affairs (OPA) now mandates that Title X projects provide a broad range of services that go beyond contraception to include basic infertility services and assistance to achieve pregnancy.
The Title X NOFO highlights a stark reality: approximately one in five married women of reproductive age with no prior births are currently affected by infertility. Despite this, a 2020 OPA Fertility Knowledge Survey revealed significant gaps in public understanding and clinical engagement. While over 65% of both men and women express a desire or intention to have children, only 32% of women and a mere 9% of men have discussed these plans with a medical provider. Furthermore, biological knowledge remains low; for instance, only 50% of women and 38% of men are aware that a woman’s ovaries do not continue to produce new eggs until menopause.
A key strategy in the 2027 NOFO is the integration of screening and referral pathways for health conditions that directly impact fertility. For women, this includes identifying and managing:
Notably, the Title X NOFO places an unprecedented focus on male reproductive health, requiring Title X services to address conditions such as low sperm count, low sperm motility, low testosterone levels, and erectile dysfunction.
To bridge the gap in reproductive knowledge, Title X clinics are now required to incorporate foundational body and health literacy into their counselling services. This education is designed to equip individuals to recognise early signs of dysfunction rather than merely seeking "symptom suppression". Counseling must cover:
The OPA is advocating for a move away from an "overreliance on pharmaceutical and surgical treatments" that may fail to address the root causes of infertility. Instead, the Title X NOFO encourages reducing overmedicalisation by focusing on underlying behavioural and lifestyle factors. Clinics are encouraged to provide education on how sleep quality, nutrition, physical activity, and pornography use influence hormonal function and overall fertility in both sexes.
Additionally, the Title X NOFO promotes the use of fertility awareness-based methods (FABMs), also known as natural family planning, as evidence-based practices that help clients understand their reproductive cycles and achieve their family formation goals.
Under the new requirements, every direct service site must describe in their work plan how they will provide basic infertility services and reproductive goals counselling. By integrating these services, OPA aims to ensure that Title X projects support the full reproductive lifespan, helping Americans not only space pregnancies but also successfully achieve healthy pregnancies and strengthen family formation.
Legacy, North America's leading digital male fertility clinic, has secured New York State CLEP approval for both its semen analysis and DNA fragmentation test – the only mandatory pre-market laboratory review programme in the United States. The approvals confirm clinical-grade validity for at-home samples, extending access to New York patients without a clinic visit.
From 1 July 2026, South Australia's Fertility Treatment Rebate Scheme provides eligible residents with a $250 rebate for pre-treatment testing and a $2,000 rebate for up to two fertility treatment cycles. Backed by an $18.5 million, four-year government commitment, the scheme directly addresses the financial barriers preventing South Australians from accessing fertility care.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
